Axiom Therapeutics

Axiom Therapeutics is a London biotechnology company using molecular physics and machine learning to design covalent small-molecule medicines.

Its computational drug-discovery platform models interactions between reactive compounds and biological targets, helping design selective inhibitors for difficult-to-drug proteins.

Founded by University of Cambridge researchers, the company develops therapeutic candidates and works with pharmaceutical partners. Its virtual compound library and simulations aim to improve lead identification and optimisation, but clinical efficacy has not been established.